Healthy
Conditions
Keywords
Healthy subjects, LPS, Effect, Intranasally
Brief summary
The purpose of this methodology study is to evaluate the effect of AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS)
Interventions
DRUGAZD8309
oral solution 30 mg/g, dose: 300mg bid for 3 days
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy men or healthy, permanently sterilized, women aged 18 to 50 years inclusive, non-smokers or ex-smokers, Body Mass Index 18 to 30 kg/m2 and minimum body weight of 50 kg * Blood neutrophil count above 2.2x10\^9/L
Exclusion criteria
* Clinical relevant disease and/or abnormality
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neutrophil numbers in nasal lavage | 3 times each in the end of two treatment periods |
Secondary
| Measure | Time frame |
|---|---|
| Cells and inflammatory biomarkers in nasal lavage | 3 times in the end of the two treatment periods |
| Cells and inflammatory biomarkers in blood | 2 times in the beginning and 5 times in the end of the two treatment periods |
Countries
Sweden
Outcome results
None listed